共 49 条
[1]
Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182
[2]
Clark GM(1989)Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707-712
[3]
Wong SG(2005)The distinctive nature of HER2-positive breast cancers N Engl J Med 353 1652-1654
[4]
Slamon DJ(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
[5]
Godolphin W(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[6]
Jones LA(2009)Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients : BCIRG 006 study Cancer Res 69 500s-820
[7]
Burstein HJ(2006)Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809-5706
[8]
Romond EH(2009)High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 5700-5699
[9]
Perez EA(2009)Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 5693-e542
[10]
Bryant J(2010)Use of adjuvant trastuzumab with chemotherapy in women with small, node negative, HER2-positive breast cancers J Clin Oncol 28 15s-7819